RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy

RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy

In May 2023, the United States Food and Drug Administration approved a Pfizer©-sponsored (Pfizer, New York, NY, USA) bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) RSV vaccine (AbrysvoTM [Pfizer]) for use during pregnancy to prevent neonatal/infant RSV infection. In...

Full description

Saved in:
Bibliographic Details
Main Authors: Greg J. Marchand, Ahmed Taher Massoud, Ahmed Taha Abdelsattar, Peter A. McCullough
Format: Article
Language:English
Published: Korean Society of Obstetrics and Gynecology 2024-11-01
Series:Obstetrics & Gynecology Science
Subjects:
vaccination
respiratory syncytial virus vaccines
neonatology
meta-analysis
Online Access:http://ogscience.org/upload/pdf/ogs-24213.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://ogscience.org/upload/pdf/ogs-24213.pdf

Similar Items